Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) Equity Average (2016 - 2025)

Celldex Therapeutics has reported Equity Average over the past 15 years, most recently at $562.8 million for Q4 2025.

  • Quarterly results put Equity Average at $562.8 million for Q4 2025, down 26.58% from a year ago — trailing twelve months through Dec 2025 was $562.8 million (down 26.58% YoY), and the annual figure for FY2025 was $637.1 million, up 8.33%.
  • Equity Average for Q4 2025 was $562.8 million at Celldex Therapeutics, down from $626.9 million in the prior quarter.
  • Over the last five years, Equity Average for CLDX hit a ceiling of $826.1 million in Q2 2024 and a floor of $188.2 million in Q2 2021.
  • Median Equity Average over the past 5 years was $395.2 million (2022), compared with a mean of $471.7 million.
  • Biggest five-year swings in Equity Average: skyrocketed 205.11% in 2024 and later decreased 26.58% in 2025.
  • Celldex Therapeutics' Equity Average stood at $428.1 million in 2021, then fell by 21.56% to $335.8 million in 2022, then grew by 0.64% to $337.9 million in 2023, then skyrocketed by 126.8% to $766.5 million in 2024, then dropped by 26.58% to $562.8 million in 2025.
  • The last three reported values for Equity Average were $562.8 million (Q4 2025), $626.9 million (Q3 2025), and $679.2 million (Q2 2025) per Business Quant data.